Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stable liquid pharmaceutical formulation of igg antibodies

a technology of igg antibodies and liquid formulations, applied in the field of stable liquid and high-concentration antibody formulations, can solve problems such as protein aggregates and particulates formation

Inactive Publication Date: 2011-03-24
ABBOTT BIOTHERAPEUTICS CORP
View PDF6 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g., greater than 50 mg / ml, of an antibody in 20-60 mM succinate buffer or 30-70 mM histidine buffer (pH from about pH 5.5 to about pH 6.5), a tonicity modifier, and about 0.01-0.1% polysorbate. This formulation retains the physical, chemical, and biological stability of antibody and prevents the immunoglobulins intended for administration to human subjects from forming aggregates and particulates in the final product. Preferred antibodies of this invention include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; and HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

Problems solved by technology

This instability is manifested in the formation of soluble / insoluble particles, and is often increased when the protein preparation is stored over time and during shipping.
The formation of protein aggregates and particulates has long been a problem in the development of parenteral immunoglobulin products, especially when the immunoglobulins are formulated at high concentrations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable liquid pharmaceutical formulation of igg antibodies
  • Stable liquid pharmaceutical formulation of igg antibodies
  • Stable liquid pharmaceutical formulation of igg antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Optimization of pH

[0054]To identify the optimum formulation for pH range and to identify major degradation pathways, a pH profile study was conducted. Sample formulations contained 5.0 mg / ml anti-IL2 receptor antibody (Daclizumab) in one of three buffers: 50 mM sodium acetate buffer at pH 4.0 or 5.0, 50 mM histidine at pH 5.5, 6.0, or 6.5, or 50 mM sodium phosphate buffer at pH 7.0 or 8.5. Independent formulations were incubated at either 5° C. or 45° C. with 100 RPM shaking for 4 weeks. The physical and chemical stability of each sample was assessed at 0 and 4 weeks by analytical methods including: pH and visual analysis, UV spectroscopy at 340 nm, size exclusion chromatography (SEC-HPLC), fluorescence spectroscopy, dynamic light scattering (DLS), differential scanning calorimetry (DSC), Promega IsoQuant Assay, capillary isoelectric focusing (cIEF), SDS-PAGE (reduced and non-reduced), and bioactivity assessments (ELISA).

[0055]SEC-HPLC performed on samples after four weeks of incuba...

example 2

Optimization of Buffers

[0059]In this experiment, independent formulations contained 5.0 mg / ml Daclizumab antibody in 50 mM sodium succinate, pH 6.0; and 50 mM histidine, pH 6.0, with and without N2 gassing. Sodium citrate buffer was not included because of reports of pain on subcutaneous injection. The bioactivity (potency) at time 0, and after 4, 8, and 12 weeks of incubation at 37° C. was measured by ELISA using microplates coated with recombinant human IL2 alpha receptor (IL-2 sRα) antigen, and goat anti-human IgG-HRP conjugate.

[0060]FIG. 4 shows the effect of different buffers over time on potency following incubation at 37° C. Highest stability of the antibody formulation was achieved through 8 weeks with 50 mM sodium succinate buffer at pH 6.0. Formulations in histidine alone rapidly (less than 8 weeks) lost their potency as the buffer oxidized. Potency of the formulation remained greater than 80% for at least 12 weeks in either sodium succinate buffer or histidine buffer gass...

example 3

Screening of Excipients

Objectives

[0061]This study was conducted to screen various excipients for the formulation of Daclizumab antibody at 50 mg / mL. From the pH optimization study conducted earlier (Example 1), the formulation stability was maximized in the pH range of 6.0-6.5. Therefore in this study, excipients were screened in two buffers; 50 mM phosphate, pH 6.5 and 50 mM succinate, pH 6.0. The stability of antibody was monitored in the two buffers for 3 weeks at 5° C. and 45° C. with shaking at 100 RPM at a concentration of 50 mg / mL. The excipients examined included: surfactants (Tween 80® and Tween 20®), salts (NaCl and MgCl2), antioxidants (EDTA and methionine), amino acids (glycine, lysine, serine and proline), and co-solvents (glycerol and ethanol). Various analytical techniques (clarity, pH, SEC-HPLC, UV-Vis, and cIEF) were used to characterize the excipient-containing formulations.

Sample Preparation

[0062]The Daclizumab antibody was in a 67 mM sodium phosphate formulation ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to View More

Abstract

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg / ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8° C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

Description

[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 337,509 filed Nov. 8, 2001.FIELD OF THE INVENTION[0002]The present invention relates generally to the field of pharmaceutical formulation of antibodies. Specifically, the present invention relates to a stable, liquid, high concentration antibody formulation. This invention is exemplified by a stabilized liquid formulation of Daclizumab, an anti-IL2 receptor antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; and HuEP5C7, a humanized anti-L selectin monoclonal antibody.BACKGROUND OF THE INVENTION[0003]Many protein preparations intended for human use require stabilizers to prevent denaturation, aggregation and other alternations to the proteins prior to the use of the preparation. This instability is manifested in the formation of soluble / insoluble particles, and is often increased when the protein preparation is stored over time and during shipping. A major aim in the development of protein dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K47/08A61K9/00A61K9/08A61K47/02A61K47/12A61K47/26A61K47/34A61P37/06C07K16/24C07K16/28
CPCA61K9/0019A61K39/39591A61K47/02A61K47/12A61K47/26C07K2317/24C07K16/244C07K16/246C07K16/249C07K16/2854A61K2039/505A61P37/06A61K39/395A61K9/08
Inventor KAISHEVA, ELIZABET A.GUPTA, SUPRIYADUVUR, SHANTI G.SUBRAMANIAN, MALATHY
Owner ABBOTT BIOTHERAPEUTICS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com